Sign in6 stories
The September 24, 2026 agreement resolves patent litigation and grants Ascendis a non-exclusive license to BioMarin patents covering TransCon CNP, with royalties running through May 2030.
SEC filing
The clinical-stage biotech said Subramanian took over as principal financial officer on September 9, 2026, while Macleod stays on through October to help with the transition.
SEC filing
Ascendis will pay BioMarin royalties on Yuviwel sales in the U.S., EU, Brazil and South Korea under a binding term sheet signed August 30, 2026.
SEC filing
BioMarin will pay $275 million upfront plus up to $215 million in milestones for ALE1, a small molecule being tested as a potential first oral therapy for hypophosphatasia.
SEC filing
The company reported 20% revenue growth in Q2 2026, advanced VOXZOGO toward a hypochondroplasia filing, and discontinued BMN 401 after it missed a co-primary endpoint.
SEC filing
Amicus Therapeutics posted 2025 financials showing improved net product sales and a narrower net loss, while confirming terms of its pending acquisition by BioMarin.
SEC filing